Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Zogenix

Nasdaq:ZGNX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ZGNX
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Zogenix has significant price volatility in the past 3 months.
ZGNX Share Price and Events
7 Day Returns
3.1%
NasdaqGM:ZGNX
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
-40.5%
NasdaqGM:ZGNX
-2%
US Pharmaceuticals
-10%
US Market
ZGNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Zogenix (ZGNX) 3.1% 2.7% -54.8% -40.5% 130.1% 82.7%
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • ZGNX underperformed the Pharmaceuticals industry which returned -2% over the past year.
  • ZGNX underperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
ZGNX
Industry
5yr Volatility vs Market

ZGNX Value

 Is Zogenix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Zogenix to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Zogenix.

NasdaqGM:ZGNX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 12 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ZGNX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.63
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.629 (1 + (1- 21%) (0.94%))
0.754
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 5.44%)
6.09%

Discounted Cash Flow Calculation for NasdaqGM:ZGNX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Zogenix is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:ZGNX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.09%)
2020 -178.67 Analyst x3 -168.41
2021 -80.39 Analyst x3 -71.42
2022 28.79 Analyst x3 24.11
2023 230.38 Analyst x3 181.85
2024 341.57 Analyst x3 254.14
2025 428.69 Est @ 25.51% 300.64
2026 507.47 Est @ 18.38% 335.45
2027 575.40 Est @ 13.39% 358.52
2028 632.32 Est @ 9.89% 371.36
2029 679.40 Est @ 7.45% 376.10
Present value of next 10 years cash flows $1,962.00
NasdaqGM:ZGNX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $679.40 × (1 + 1.74%) ÷ (6.09% – 1.74%)
$15,882.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $15,882.96 ÷ (1 + 6.09%)10
$8,792.35
NasdaqGM:ZGNX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,962.00 + $8,792.35
$10,754.35
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,754.35 / 53.90
$199.53
NasdaqGM:ZGNX Discount to Share Price
Calculation Result
Value per share (USD) From above. $199.53
Current discount Discount to share price of $23.82
= -1 x ($23.82 - $199.53) / $199.53
88.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Zogenix is available for.
Intrinsic value
>50%
Share price is $23.82 vs Future cash flow value of $199.53
Current Discount Checks
For Zogenix to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Zogenix's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Zogenix's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Zogenix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Zogenix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ZGNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-9.74
NasdaqGM:ZGNX Share Price ** NasdaqGM (2020-04-07) in USD $23.82
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Zogenix.

NasdaqGM:ZGNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ZGNX Share Price ÷ EPS (both in USD)

= 23.82 ÷ -9.74

-2.45x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zogenix is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Zogenix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Zogenix's expected growth come at a high price?
Raw Data
NasdaqGM:ZGNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.45x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts
67.7%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Zogenix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Zogenix's assets?
Raw Data
NasdaqGM:ZGNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $5.41
NasdaqGM:ZGNX Share Price * NasdaqGM (2020-04-07) in USD $23.82
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:ZGNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ZGNX Share Price ÷ Book Value per Share (both in USD)

= 23.82 ÷ 5.41

4.4x

* Primary Listing of Zogenix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Zogenix is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Zogenix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Zogenix has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ZGNX Future Performance

 How is Zogenix expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
67.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Zogenix expected to grow at an attractive rate?
  • Zogenix's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Zogenix's earnings growth is expected to exceed the United States of America market average.
  • Zogenix's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ZGNX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ZGNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 12 Analysts 67.7%
NasdaqGM:ZGNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 12 Analysts 47.4%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ZGNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ZGNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 560 420 233 4
2023-12-31 432 363 139 5
2022-12-31 297 197 32 7
2021-12-31 143 10 -119 11
2020-12-31 20 -144 -192 12
2020-04-08
NasdaqGM:ZGNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 4 -112 -420
2019-09-30 2 -105 -386
2019-06-30 1 -98 -138
2019-03-31 -112 -129
2018-12-31 -112 -124
2018-09-30 0 -113 -141
2018-06-30 0 -105 -141
2018-03-31 7 -89 -135
2017-12-31 10 -76 -126
2017-09-30 21 -65 -110
2017-06-30 27 -62 -84
2017-03-31 22 -63 -80

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Zogenix's earnings are expected to grow significantly at over 20% yearly.
  • Zogenix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ZGNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below

All data from Zogenix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ZGNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 3.78 4.82 2.46 3.00
2023-12-31 2.44 5.59 0.45 5.00
2022-12-31 0.57 2.56 -1.37 8.00
2021-12-31 -2.15 -0.20 -4.21 12.00
2020-12-31 -4.01 -3.06 -4.72 13.00
2020-04-08
NasdaqGM:ZGNX Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -9.74
2019-09-30 -9.09
2019-06-30 -3.32
2019-03-31 -3.24
2018-12-31 -3.27
2018-09-30 -3.93
2018-06-30 -4.36
2018-03-31 -4.53
2017-12-31 -4.62
2017-09-30 -4.40
2017-06-30 -3.38
2017-03-31 -3.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Zogenix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Zogenix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Zogenix has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ZGNX Past Performance

  How has Zogenix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Zogenix's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Zogenix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Zogenix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Zogenix's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Zogenix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Zogenix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ZGNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 3.65 -419.50 60.79
2019-09-30 1.70 -385.88 55.03 99.33
2019-06-30 1.07 -137.66 50.28 99.33
2019-03-31 -128.74 44.08 100.02
2018-12-31 -123.72 38.95
2018-09-30 0.00 -141.07 37.22 16.28
2018-06-30 0.00 -141.46 32.28 37.46
2018-03-31 7.13 -135.08 29.20 75.29
2017-12-31 9.82 -126.02 25.89
2017-09-30 20.81 -109.84 27.52 60.86
2017-06-30 27.38 -83.80 27.98 49.76
2017-03-31 22.34 -79.59 29.33 45.29
2016-12-31 28.85 -68.69 28.90 39.94
2016-09-30 23.95 -56.95 26.31 37.00
2016-06-30 26.50 -53.31 25.46 34.84
2016-03-31 31.77 -41.76 26.20 30.70
2015-12-31 27.18 -41.70 27.85 26.36
2015-09-30 31.04 -39.42 25.02 22.59
2015-06-30 26.80 -27.96 26.60 17.58
2015-03-31 26.17 56.27 28.08 14.50
2014-12-31 28.95 61.49 34.34 11.89
2014-09-30 28.93 35.44 42.41 12.06
2014-06-30 31.21 26.12 45.15 11.69
2014-03-31 33.42 -64.75 48.09 12.11
2013-12-31 33.01 -72.60 46.22 8.37
2013-09-30 32.59 -45.88 48.41 14.77
2013-06-30 33.87 -54.31 49.26 15.88

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Zogenix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Zogenix has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Zogenix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Zogenix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Zogenix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ZGNX Health

 How is Zogenix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Zogenix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Zogenix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Zogenix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Zogenix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -1.6170118167078E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Zogenix Company Filings, last reported 3 months ago.

NasdaqGM:ZGNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 245.06 0.00 251.16
2019-09-30 250.59 0.00 254.96
2019-06-30 465.72 0.00 462.97
2019-03-31 496.88 0.00 480.70
2018-12-31 522.80 0.00 514.19
2018-09-30 538.78 0.00 539.13
2018-06-30 279.87 0.00 272.10
2018-03-31 273.77 0.00 271.95
2017-12-31 301.52 0.00 293.50
2017-09-30 59.62 19.22 64.73
2017-06-30 79.48 22.60 65.76
2017-03-31 101.12 22.34 80.11
2016-12-31 120.76 22.09 91.55
2016-09-30 141.92 21.85 109.87
2016-06-30 156.95 21.60 127.80
2016-03-31 173.86 20.76 132.18
2015-12-31 182.76 22.22 155.35
2015-09-30 189.81 22.21 167.81
2015-06-30 108.08 22.04 86.43
2015-03-31 34.29 24.44 21.31
2014-12-31 55.28 23.15 42.21
2014-09-30 57.54 2.38 50.53
2014-06-30 68.32 2.29 81.24
2014-03-31 2.42 28.89 50.68
2013-12-31 18.43 28.80 72.02
2013-09-30 -13.89 28.72 17.35
2013-06-30 -16.09 28.64 16.12
  • Zogenix's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (42.1% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Zogenix has sufficient cash runway for 2.1 years based on current free cash flow.
  • Zogenix has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 12.1% each year.
X
Financial health checks
We assess Zogenix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Zogenix has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ZGNX Dividends

 What is Zogenix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Zogenix dividends. Estimated to be 0% next year.
If you bought $2,000 of Zogenix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Zogenix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Zogenix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ZGNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 12 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ZGNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 2.00
2020-12-31 0.00 2.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Zogenix has not reported any payouts.
  • Unable to verify if Zogenix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Zogenix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Zogenix has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Zogenix's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Zogenix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Zogenix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Zogenix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ZGNX Management

 What is the CEO of Zogenix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Farr
COMPENSATION $6,650,252
AGE 60
TENURE AS CEO 5 years
CEO Bio

Dr. Stephen J. Farr, also known as Steve, Ph.D., co-founded Zogenix, Inc. in 2006 and has been its President since May 2006 and its Chief Executive Officer since April 2015. Dr. Farr served as the Chief Operating Officer at Zogenix, Inc. from August 2006 to March 2013. He serves as a Director of Cerebral Therapeutics, LLC. From 1995 to August 2006, he held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation. He served as the Chief Scientific Officer and Senior Vice President for Aradigm Corporation since April 2003. He served as Vice President of Research and Development of Aradigm Corporation since July 2000. He served as Vice President of Pharmaceutical Sciences at Aradigm from January 1999 to June 2000 and served as its Senior Director of Pharmaceutical Sciences from January 1995 to December 1998. He served as Head of Research and Development, a department of clinicians, scientists and engineers engaged in the design and development of drug/device systems for pulmonary administration and needle-free injection. He served as Scientific Director for Aradigm and Novo Nordisk's inhaled insulin program from inception to Phase 3 start. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. He has over 20 years experience in drug delivery science and drug/device product development. Dr. Farr is a Director on the Board of Oscillari, LLC, and Flow Pharma, Inc. He serves as a Director of SteadyMed Therapeutics, Inc. He has been a Director of Zogenix, Inc. since May 2006. He served as a Director of SteadyMed Ltd. from May 2012 to August 30, 2018. He serves as a Member of Scientific Advisory Board of Aradigm Corporation. He was a Founder of Cardiff Scintigraphics Ltd. and served as its Director. He is a visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. From September 1986 to December 1994, he was Lecturer and later Senior Lecturer/Professor in the Welsh School of Pharmacy, Cardiff University, United Kingdom. He is an Author of over 180 scientific publications and patents. He is a registered pharmacist in the UK and is a Fellow of the American Association of Pharmaceutical Scientists. Dr. Farr is a Member of the Royal Pharmaceutical Society. Dr. Farr holds B.Sc. in Pharmacy from DeMontfort University and a Ph.D. in pharmaceutics from the University of Wales.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Zogenix management team in years:

6.3
Average Tenure
56
Average Age
  • The average tenure for the Zogenix management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Steve Farr

TITLE
Co-Founder
COMPENSATION
$7M
AGE
60
TENURE
5 yrs

Mike Smith

TITLE
Executive VP
COMPENSATION
$2M
AGE
51
TENURE
3.3 yrs

Bradley Galer

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$3M
AGE
57
TENURE
6.3 yrs

Gail Farfel

TITLE
Executive VP & Chief Development Officer
COMPENSATION
$2M
AGE
55
TENURE
4.8 yrs

Ashish Sagrolikar

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$4M
TENURE
1.8 yrs

Jeff Durflinger

TITLE
Vice President of Technical Operations & Product Supply
AGE
58
TENURE
9.1 yrs

Catherine O'Connor

TITLE
Senior Director of Corporate Communications

Bret Megargel

TITLE
Vice President of Corporate Development
AGE
50
TENURE
13.7 yrs

Stephen Jenner

TITLE
Vice President of Marketing
AGE
51
TENURE
9.3 yrs

John Turanin

TITLE
VP & GM of Zogenix Technologies
COMPENSATION
$326K
AGE
61
TENURE
13.9 yrs
Board of Directors Tenure

Average tenure and age of the Zogenix board of directors in years:

11.9
Average Tenure
61.5
Average Age
  • The average tenure for the Zogenix board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Cam Garner

TITLE
Co-founder & Chairman
COMPENSATION
$518K
AGE
71
TENURE
13.7 yrs

Steve Farr

TITLE
Co-Founder
COMPENSATION
$7M
AGE
60
TENURE
13.9 yrs

Lou Bock

TITLE
Independent Director
COMPENSATION
$478K
AGE
54
TENURE
13.7 yrs

Erle Mast

TITLE
Independent Director
COMPENSATION
$488K
AGE
57
TENURE
11.9 yrs

Jeff Gudin

TITLE
Chairperson of External Safe Use Board

Mark Wiggins

TITLE
Independent Director
COMPENSATION
$475K
AGE
63
TENURE
8.9 yrs

Jim Breitmeyer

TITLE
Independent Director
COMPENSATION
$465K
AGE
65
TENURE
6.1 yrs

David Brushwood

TITLE
Member of External Safe Use Board
TENURE
5.8 yrs

John Burke

TITLE
Member of External Safe Use Board

Debra Gordon

TITLE
Member of External Safe Use Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Zogenix individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
24. Mar 20 Buy Mark Wiggins Individual 23. Mar 20 23. Mar 20 2,500 $20.48 $51,196
20. Mar 20 Buy Bradley Galer Individual 18. Mar 20 18. Mar 20 1,000 $19.69 $19,685
18. Mar 20 Buy Cam Garner Individual 13. Mar 20 13. Mar 20 8,000 $21.83 $174,647
X
Management checks
We assess Zogenix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Zogenix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ZGNX News

Simply Wall St News

Have Insiders Been Selling Zogenix, Inc. (NASDAQ:ZGNX) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Zogenix, Inc. … View our latest analysis for Zogenix The Last 12 Months Of Insider Transactions At Zogenix In the last twelve months, the biggest single sale by an insider was when the insider, Roger Hawley, sold US$3.2m worth of shares at a price of US$53.10 per share. … NasdaqGM:ZGNX Recent Insider Trading, August 28th 2019 Insider Ownership For a common shareholder, it is worth checking how many shares are held by company insiders.

Simply Wall St -

If You Had Bought Zogenix (NASDAQ:ZGNX) Stock Three Years Ago, You Could Pocket A 449% Gain Today

(NASDAQ:ZGNX) share price is up a whopping 449% in the last three years, a handsome return for long term holders. … Given the share price has increased by a solid 76% per year, over 3 years, its fair to say investors remain excited about the future, despite the potential need for cash. … Longer term investors wouldn't be so upset, since they would have made 29%, each year, over five years.

Simply Wall St -

Why Fundamental Investors Might Love Zogenix, Inc. (NASDAQ:ZGNX)

ZGNX is a company with impressive financial health as well as an optimistic growth outlook. … This indicates that ZGNX has sufficient cash flows and proper cash management in place, which is a crucial insight into the health of the company. … ZGNX has plenty of financial flexibility, without debt obligations to meet in the short term, as well as the headroom to raise debt should it need to in the future.

Simply Wall St -

Should You Be Pleased About The CEO Pay At Zogenix, Inc.'s (NASDAQ:ZGNX)

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … See our latest analysis for Zogenix How Does Steve Farr's Compensation Compare With Similar Sized Companies? … We examined companies with market caps from US$1.0b to US$3.2b, and discovered that the median CEO total compensation of that group was US$4.1m.

Simply Wall St -

What You Must Know About Zogenix, Inc.'s (NASDAQ:ZGNX) Beta Value

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … See our latest analysis for Zogenix What ZGNX's beta value tells investors Given that it has a beta of 1.95, we can surmise that the Zogenix share price has been fairly sensitive to market volatility (over the last 5 years). … What this means for you: Since Zogenix tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock.

Simply Wall St -

Have Insiders Been Selling Zogenix, Inc. (NASDAQ:ZGNX) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … So we'll take a look at whether insiders have been buying or selling shares in Zogenix, Inc. … Over the last year, we can see that the biggest insider sale was by the , Roger Hawley, for US$3.2m worth of shares, at about US$53.10 per share.

Simply Wall St -

Can You Imagine How Elated Zogenix's (NASDAQ:ZGNX) Shareholders Feel About Its 449% Share Price Gain?

(NASDAQ:ZGNX) share price is up a whopping 449% in the last three years, a handsome return for long term holders. … Zogenix has plenty of cash in the bank, with net cash sitting at US$389m, when it last reported (December 2018). … And given that the share price has shot up 76% per year, over 3 years, its fair to say investors are liking management's vision for the future.

Simply Wall St -

Is Zogenix, Inc.'s (NASDAQ:ZGNX) CEO Salary Justified?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Steve Farr's Compensation Compare With Similar Sized Companies. … is worth US$2.1b, and total annual CEO compensation is US$2.0m.

Simply Wall St -

An Intrinsic Calculation For Zogenix, Inc. (NASDAQ:ZGNX) Shows It's 44.82% Undervalued

by estimating the company's future cash flows and discounting them to their present value. … Discounted Cash Flows (DCF) … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model.

Simply Wall St -

Why I Like Zogenix, Inc. (NASDAQ:ZGNX)

Attractive stocks have exceptional fundamentals. … In the case of Zogenix, Inc. … (NASDAQ:ZGNX), there's

Simply Wall St -

ZGNX Company Info

Description

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Details
Name: Zogenix, Inc.
ZGNX
Exchange: NasdaqGM
Founded: 2006
$1,283,856,219
53,898,246
Website: http://www.zogenix.com
Address: Zogenix, Inc.
5858 Horton Street,
Suite 455,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ZGNX Common Stock Nasdaq Global Market US USD 23. Nov 2010
DB Z081 Common Stock Deutsche Boerse AG DE EUR 23. Nov 2010
LSE 0M3O Common Stock London Stock Exchange GB USD 23. Nov 2010
BRSE Z081 Common Stock Berne Stock Exchange CH CHF 23. Nov 2010
Number of employees
Current staff
Staff numbers
141
Zogenix employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 05:42
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.